A combination biomarker panel including the quantitative amount of ct-DNA, CA19-9 and Thrombospondin-2 could significantly improve the diagnostic power of CA19-9, especially in the detection of potentially curable stage I PDAC patients and the discrimination from CP and IPMN [50]. Here, THBS2 is linked to pancreatic intraductal papillary-mucinous neoplasm.